Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Abbv crawled time : 12:15 save search
Coherus and Junshi Biosciences Announce FDA Acceptance of BLA Filing for Toripalimab for Treatment of Nasopharyngeal Carcinoma
Published: 2021-11-01 (Crawled : 12:15) - biospace.com/
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 2.72%
H: 0.41%
C: -0.38%
CHRS | $2.06 3.0% 2.91% 2.9M
|
Health Technology
|
| O: 1.49%
H: 3.83%
C: 0.0%
treatment fda fda acceptance
Junshi Biosciences and Coherus Announce FDA Acceptance of BLA Filing for Toripalimab for Treatment of Nasopharyngeal CarcinomaFDA has granted the toripalimab BLA Priority Review with a target action date of April 2022
Published: 2021-11-01 (Crawled : 12:15) - biospace.com/
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 2.72%
H: 0.41%
C: -0.38%
CHRS | $2.06 3.0% 2.91% 2.9M
|
Health Technology
|
| O: 1.49%
H: 3.83%
C: 0.0%
treatment fda fda acceptance granted
AbbVie's Cariprazine (VRAYLAR®) Met Primary Endpoint in Phase 3 Study as an Adjunctive Treatment for Major Depressive Disorder
Published: 2021-10-29 (Crawled : 12:15) - biospace.com/
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 2.31%
H: 0.0%
C: 0.0%
treatment phase 3 depression major depressive disorder
AbbVie's RINVOQ® (upadacitinib) Met Primary and All Ranked Secondary Endpoints in Phase 3 Study in Ankylosing Spondylitis
Published: 2021-10-07 (Crawled : 12:15) - prnewswire.com
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.42%
H: 1.83%
C: 0.99%
phase 3
AbbVie's Upadacitinib (RINVOQ®) Met Primary and Most Ranked Secondary Endpoints in Phase 3 Study for Non-Radiographic Axial Spondyloarthritis
Published: 2021-10-07 (Crawled : 12:15) - prnewswire.com
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.42%
H: 1.83%
C: 0.99%
phase 3
Coherus and Junshi Biosciences Announce Completion of Rolling BLA Submission to U.S. FDA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma
Published: 2021-09-01 (Crawled : 12:15) - globenewswire.com
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.18%
H: 0.44%
C: -7.21%
CHRS | $2.06 3.0% 2.91% 2.9M
|
Health Technology
|
| O: -0.13%
H: 1.75%
C: 1.0%
treatment fda submission bla submission
Junshi Biosciences and Coherus Announce U.S. FDA Breakthrough Therapy Designation Granted for Toripalimab for 1st Line Treatment of Nasopharyngeal Carcinoma
Published: 2021-08-12 (Crawled : 12:15) - globenewswire.com
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.21%
H: 1.55%
C: 1.47%
CHRS | $2.06 3.0% 2.91% 2.9M
|
Health Technology
|
| O: 1.05%
H: 1.26%
C: 0.96%
treatment fda therapy breakthrough therapy grant designation
North American Healthcare CDMO (Contract Development and Manufacturing Organization) Market Report 2021-2026: Clinical, Preclinical, Laboratory Services, API, Finish Dosage Formulations, Devices
Published: 2021-06-10 (Crawled : 12:15) - prnewswire.com
TMO | News | $544.78 0.6% 0.0% 1.7M
|
Health Technology
|
| O: 0.13%
H: 3.77%
C: 3.59%
JBL S | $118.75 -8.37% 0.76% 3.3M
|
Electronic Technology
|
| O: 0.66%
H: 0.0%
C: -0.59%
CTLT | $55.48 -0.57% -0.4% 1.6M
|
Health Technology
|
| O: 0.22%
H: 1.76%
C: 1.24%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.32%
H: 2.3%
C: 1.64%
contract device preclinical pre-clinical
Junshi Biosciences and Coherus Announce Toripalimab First-Line Nasopharyngeal Carcinoma Clinical Data to be Showcased in Plenary Session at 2021 ASCO Annual Meeting
Published: 2021-04-29 (Crawled : 12:15) - biospace.com/
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.4%
H: 0.2%
C: -1.33%
CHRS | $2.06 3.0% 2.91% 2.9M
|
Health Technology
|
| O: -0.14%
H: 1.22%
C: -0.27%
Coherus Announces Toripalimab Achieved Primary Endpoints of Progression Free Survival and Overall Survival in Interim Analysis of Phase 3 Clinical Trial in First-Line Esophageal Squamous Cell Carcinoma
Published: 2021-04-23 (Crawled : 12:15) - globenewswire.com
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.31%
H: 1.88%
C: 1.52%
CHRS | $2.06 3.0% 2.91% 2.9M
|
Health Technology
|
| O: 0.48%
H: 2.31%
C: 1.29%
phase 3 trial cell carcinoma
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.